CD80 variant proteins and uses thereof
US12378299B2 · kind B2 · utility
0Cited by
1References
10Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 24, 2020 |
| Grant date | Aug 5, 2025 |
| Priority date | — |
| Expiry date | Dec 4, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides variant CD80 polypeptides that have altered affinity for their cognate binding partners, and immunomodulatory fusion proteins comprising the variant CD80 polypeptides. The present disclosure also provides pharmaceutical compositions comprising such polypeptides and/or proteins and methods for modulating immune responses and/or treatment of cancer, infectious diseases, and/or immunological diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.